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1. Introduction
ABSTRACT
Objective: To analyze expression heterogeneity of Integrin beta 3 (ITGB3) and B-celllymphoma
2 (BCL-2) in lung adenocarcinoma tissue and adenocarcinoma cell line and further provide
theoretical direction for molecular biological research of lung adenocarcinoma. Methods:
Tissue microarray was used to observe relation among expression, heterogeneitpy and clinical
characteristics of ITGB3 and BCL-2 in lung cancer. Results: ITGB3 and BCL-2 increased
significantly in A549 cells in CAFsgroup with ~ -actin as control; the expression level of BCL-2
also increased in ITGB3 transfected cells with GFP plasmid transfected A549 cells as control;
immunohistochemistry staining showed that positive rates of ITGB3, ITGBI and BCL-2 in normal
lung tissues were 0, the positive rates in lung adenocarcinoma were 7.04%, 84.51% and 4.23%,
respectively; in the results of immunohistochemistry staining, the expression of Girdin protein in
lung adenocarcinoma was homogeneous, however protein expression of ITGB3, ITCBl and BCL-2
showed different patterns in the same location with significant heterogeneity; majority of ITGB3,
ITGBI or BCL-2 positive tissue showed heterogeneity that expression in trailing edge was higher
than that of trailing edge in lung adenocarcinoma tissue, the patients with BCL-2 heterogeneity
showed higher lymph node metastasis ratio and lower clinical stage (P<O.05); and the expression
of ITGB3 and the clinical characteristics of patients were not significant related (P>0.05).
Conclusions: Expression of ITGB3 and BCL-2 in lung adenocarcinoma and adenocarcinoma
cell line showed heterogeneity that expression in trailing edge was higher than that of trailing
edge, which may play an important role in promoting tumor lymph node metastasis and vascular
invasion, and provides a new research direction for exploration of lung adenocarcinoma
metastasis mechanism.
the exact influencing mechanism, we conducted the related
research, the procedure and conclusion are reported as
following.
Liver cancer IS a malignant cancer that threatens
human life and health with ascending trend of modality
and mortality and it requires higher standard in clinical
prevention and treatment of lung cancer[I,2J. Integrin beta
3 (fGB3) and B-celllymphoma 2 (BCL-2) function in cell
adhesion and apoptosis respectively. Recent research
considered that ITGB3 and BCL-2 had significantly effects
in occurrence and development of cancerfs.tl. To explore
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2. Materials and methods
2.1. Experimental methods
Paraffin embedded samples from 576 lung cancer patients
during January, 2005-January, 2013 in our hospital were
selected, including 213 cases of adenocarcinoma, 222 cases
of squamous carcinoma, 27 cases of large cell carcinoma,
45 cases of small cell carcinoma, 42 cases of carcinoid, 18
cases of bronchial adenoma, 9 cases of adenosquamous
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Table 1
Positive rate of ITGB3, ITGB1 and BCL-2 expression in various lung cancers and normal lung tissue (%).
Sample type
Number of 
samples
ITGB3 ITGB1 BCL-2
Number of positive 
cases
Positive rate
Number of positive 
cases
Positive rate
Number of positive 
cases
Positive rate
Adenocarcinoma 213 15     7.04 180   84.51   9   4.23
Squamous carcinoma 222 93   41.89 183   82.43 51 22.97
Large cell carcinoma   27   3   11.11   21   77.78   0   0.00
Small cell carcinoma   45 33   73.33    9   20.00   3   6.67
Carcinoid   42 33   78.57   24   57.14   6 14.29
Bronchial adenoma   18   0     0.00    6   33.33   0   0.00
Adenosquamous carcinoma     9   9 100.00    9 100.00   6 66.67
Normal lung tissue   17   0     0.00    0     0.00   0   0.00
Conditional Medium
Set 1                         Set 2
NF          CAF               NF          CAF
Ingerin 毬3
BCL-2
毬-actin
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carcinoma, which were all diagnosed referring to Lung
cancer clinical diagnostic criteria proposed by WHO in
1999[5,6]. In the same period, paraffin embedded samples of
normal lung tissue from 17 normal patient were collected.
2.2. Experimental treatment
2.2.1. Production oftissue microarray
Production of tissue microarray was referred to
experimental method in related references[7,81, mouse anti-
human Skp2 monoclonal antibody and 0.1% citric acid buffer
solution were used for 10 min microwave repair, and then
primary antibody was added, DAB developing was used after
being preserved at 4 ·C for 12 h. PBS was used as negative
control, and immunohistochemical labeling was used. Mouse
anti-human Skp2 monoclonal antibody was purchased from
OriGene Technologies, USA
ITGB3, ITGBI and BCL-2 expression in various types oflung
cancer and normal lung tissue were observed, 213 samples
of lung adenocarcinoma expression heterogeneity at leading
edge and trailing edge of cancer tissue were specially
analyzed. Girdin protein was used as negative control,
immunohistochemical staining was applied in paraffin
section of lung adenocarcinoma to observe expression of
ITGB3 and BCL-2 at the same location. Relation between
expression heterogeneity of lung adenocarcinoma tissue and
adenocarcinoma cells and clinical indexes were analyzedlicl,
2.4. Statistical analysis
All date in our study were analyzed by SPSSI3.0.
Enumeration data was analyzed by Chi-square test and
measurement data was analyzed by t test. The test level was
set as a =0.05. The difference was considered as statistically
significant when P<0.05.
3. Results
3.1. Result ofWestem blot
ITGB3 and BCL-2 increased significantly in A549 cells in
CAFs group with ~ -actin as control, as shown in Figure 1-2.
et
2.2.2. HE staining
After dewaxing and hydration of tissue microarray, the
tissues were put in xylene and immersed for 10 min, xylene
was changed and immersed again for 10 min, repeated for 4
times; the processed tissue microarrays were put in absolute
ethanol for 1 min and repeated for 3 times; and then put in
either 95% ethanol and 75% ethanol for 5 min and washed
under water flow. Hematoxylin stained for 5 min and washed
in water flow for 15 min, and then stained by eosin for 5 s.
At last, the tissues were dehydrated and observed under
microscope after sealed.
2.3. Obseroational indexes F
GFP-A549 cell line was established referring to related
method in references[7,81, FACS was used to separate GFP
marked A549, Western blot was used to detect expression
difference between ITGB3 and BCL-2. ITGB3 plasmid was
used to transfect A549 cells to observe the influence of ITGB3
overexpression on BCL-2 expressionlsl. Positive rates of
'-- -.II Ingerin ~ 3
I L-
~==~
___I ~ -actin
Figure 1. Expression of ITGB3 and BCL-2 in conditionalmedium
culture.
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Table 3
Relation between heterogeneity of ITGB3 and BCL-2 and clinical characteristics of patients (%).
Clinical characteristics
ITGB3(n=15) BCL-2(n=9)
Leading edge≤trailing
edge
Leading edge>
trailing edge
P value Leading edge≤trailing 
edge
Leading edge>
trailing edge
P value
Age(year) ≥60 7(46.7) 2(13.3) 0.535 3(33.3) 1(11.1) 1.000
<60 5(33.3) 1(6.7) 4(44.4) 1(11.1)
Gender Male 6(40.0) 1(6.7) 1 2(22.2) 0 1.000
Female 8(53.3) 0 3(33.3) 4(44.4)
Clinical stage Stage 栺 3(20.0) 2(13.3) 0.704 1(11.1) 1(11.1) 0.019
△
Stage 栻 5(33.3) 0 3(33.3) 2(22.2)
Stage 栿 4(26.7) 1(6.7) 1(11.1) 1(11.1)
Clinical grade Grade 1-2 3(20.0) 3(20.0) 0.263 3(33.3) 1(11.1) 0.588
Grade 3-4 5(33.3) 4(26.7) 3(33.3) 2(22.2)
Lymph node metastasis Yes 4(26.7) 3(20.0) 0.296 3(33.3) 1(11.1) 0.039▲
No 7(46.7) 1(6.7) 5(55.6) 0
Note:△:氈
2=8.067, OR=7.138, P<0.05; ▲: 氈
2=6.255,OR=8.209, P<0.05.
Ingerin 毬3
BCL-2
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Table 2
Expression heterogeneity of ITGB3, ITGB1 and BCL-2 in leading 
edge and trailing edge of lung adenocarcinoma tissue (n).
Heterogeneity ITGB3 ITGB1 BCL-2
Leading edge<trailing edge   0   16 1
Leading edge = trailing edge   6   83 2
Leading edge>trailing edge   9   81 6
In total 15 180 9
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0, the positive rates in lung adenocarcinoma were 7.04%,
84.51% and 4.23% respectively, as shown in Table 1.
3.2. Result ofITGB3 plasmid transfection
L....- ---JI ~ -actin
'-- .....1 BCL-2
3.4. Results ofimmunohistochemical staining
The expression of Girdin protein in lung adenocarcinoma
was homogeneous, however protein expression of ITGB3,
ITGBI and BCL-2 showed different patterns in the same
location with significant heterogeneity, as shown in Figure 4.
3 - C
L..- ...JI Ingerin ~ 3
The expression level of BCL-2 was also increased in ITGB3
transfected cells with GFP plasmid transfected A549 cells as
control, as shown in Figure 3.
Figure 2. Expression ofITGB3 and BCL-2 in co-culture system.
Note: Set I:A549 cells cultured in NF medium/CAF medium; Set
2:A549 cells cultured in NHLF mediumILCAF medium.
Figure 3. Influence of ITGB3 plasmid transfection on BCL-2
expression of A549 cells.
3.3. Positive rates of ITGB3 and BCL-2 in various lung
cancers and normal lung tissue
Immunohistochemistry staining showed that positive rates
of ITGB3, ITGBI and BCL-2 in normal lung tissues were
Figure 4. Results of immunohistochemicalstaining.
-it I
Majority of ITGB3, ITGBI or BCL-2 positive tissue showed
heterogeneity that expression in trailing edge was higher
than that of trailing edge in lung adenocarcinoma tissue, as
shown in Table 2 and Figure 5.
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4. Discussion
3.6. Relation between heterogeneity and clinical
characteristics
Figure 5. Expression difference between cancer cells of leading edge
and trailing edge.
A: Leading edge<trailing edge; b: Leading edge<trailing edge.
The patients with BCL-2 heterogeneity showed higher
lymph node metastasis ratio and lower clinical stage
<p<0.05); and the expression of ITGB3 and the clinical
characteristics of patients were not significant related
(p >0.05), as shown in Table 3.
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in lung adenocarcinoma is homogeneous, however protein
expression of ITGB3, ITGB! and BCL-2 showed different
patterns in the same location with significant heterogeneity;
majority of ITGB3, ITGB! or BCL-2 positive tissue showed
heterogeneity that expression in trailing edge was higher
than that of trailing edge. The characteristics of cancer are
closely related to its metastasis and reproduction, and the
expression heterogeneity of leading edge cells and trailing
edge cells it the important factor that affects budding, tissue
type and blood vessel invasion in cancer metastasis[18-21J. It
is reasonable to consider that the effects of ITGB3 and BCL-2
in occurrence and development of lung adenocarcinoma may
affect heterogeneity of leading edged cells and trailing edge
cells, and induce metastasis and invasion of cancer cells.
The patients with BCL-2 expression heterogeneity in lung
adnocarcinoma tissue had higher lymph node metastatic
rate and lower clinical stage <p<0.05); and the expression of
ITGB3 and the clinical characteristics of patients were not
significant related <p>0.05). In research of non-small cell
lung cancer research by Felicetti et al[22-26J, patients with
high BCL-2 expression showed poor prognosis, and in our
research BCL-2 expression in leading edge cells of lung
adenocarcinoma was high, indicating that BCL-2 expressed
in leading edge cells of lung adenocarcinoma possibly
affects significantly in metastatic invasion of cancer.
Besides, many researches also found that transforming
growth factor family is also significantly in promoting ITGB3
expression[27,28J, the main mechanism are as following:
cancer fibroblast first promote epithelium-mesenchyme
neoplasis of cancer invasive edge, and fibroblast secrete a
lot of transforming growth factor to cause phosphorylation of
locally adhered kinase, causing the up-regulation of ITGB3
with main function of cell adhesion[29J. Thus, we consider
that in the beginning of cancer occurrence, ITGB3 is
activated and expression of ITGB3 is up-regulated to further
induce BCL-2 overexpression, which is the significant
influencing factor causing occurrence and development of
lung adenocarcinoma.
In conclusion, ITGB3 and BCL-2 both showed heterogeneity
that expression in trailing edge was higher than that of
trailing edge, function significantly in lymph node metastasis
and blood vessel metastasis, providing a new direction in
exploration of lung adenocarcinoma metastasis mechanism.
Adenocarcinoma is a histological type of lung cancer,
deep research in molecular biology can possibly direct
the exploration of lung cancer mechanism and affect
significantly in prevention and treatment of lung cancer.
Meanwhile, invasion and metastasis of cancer are considered
as the reasons that shorten patients' survival time[11,12J. Thus,
research of tumor microenvironment in metastasis of lung
adenocarcinoma is significant. Researches reported that
ITGB3 and BCL-2 could function in cell adhesion and cell
apoptosis, which were highly expressed in various cancer
tissues and considered as critical genes in occurrence and
metastasis of cancerl13-15J.
In our research were selected ITGB3 and BCL-2 as our
chief objectives to explore the expression heterogeneity in
lung adenocarcinoma and adenocarcinoma cells. We found
that ITGB3 and BCL-2 both significantly increased in A549
cells in CAFs group with ~ -actin as control, indicating that
CAFs may be the mediated factor in increase of ITGB3 and
BCL-2[16,l7J, and in the result of ITGB3 plasmid transfection,
we found that BCL-2 expression also increased when
transfected by ITGB3 with GFP plasmid transfected A549 as
control, indicating that CAFs may induce overexpression
of BCL-2 by up-regulating ITGB3 expression. Although
positive rates of ITGB3 and BCL-2 were low in lung
adenocarcinoma tissue microarray, we still selected part of
positive samples for further research. Immunohistochemical
staining result showed that the expression of Girdin protein
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